MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
1983 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
538 M |
Market Cap[1] |
$ 249 B |
EBITDA (LTM) |
$ 11.9 B |
P/E (LTM) |
25.331981 |
P/S (LTM) |
7.924729 |
EPS (LTM) |
17.26 |
Amgen is a biopharmaceutical company founded in the USA in 1980. The company is engaged in the development and production of drugs for the treatment of serious diseases such as cancer, rheumatoid arthritis, and osteoporosis.
AMGN is a leading provider of biotechnology products and has over 20,000 employees worldwide. The company has operations in over 100 countries and produces its products in facilities around the world.
The main goal of Amgen is to improve the lives of patients by developing innovative drugs that help fight serious illnesses. The company invests billions of dollars annually in research and development to find new treatment options.
AMGN also advocates for sustainability and environmental protection. The company is committed to reducing its CO2 emissions and making its production processes as environmentally friendly as possible. Amgen is also involved in the community and supports various programs to improve healthcare and education.
Overall, Amgen is an innovative and responsible company dedicated to developing new treatment options for serious illnesses while also striving to protect the environment and support the community.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Teva Pharmaceutical Industries Limited
TEVA
|
$ 41.75 | -0.12 % | $ 47.8 B | NYSE |  Israel |
 |
Molecular Templates
MTEM
|
- | -23.43 % | $ 495 K | Nasdaq Capital Market | USA |
 |
Gossamer Bio
GOSS
|
$ 9.54 | -4.12 % | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Genmab A/S
GMAB
|
$ 52.76 | -4.28 % | $ 3.41 B | Nasdaq Global Select Market |  Danmark |
 |
GeoVax Labs
GOVX
|
$ 0.16 | -2.44 % | $ 153 K | Nasdaq Global Select Market | USA |
 |
Grifols, S.A.
GRFS
|
$ 8.49 | -1.39 % | $ 5.77 B | Nasdaq Global Select Market |  Spain |
 |
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | USA |
 |
GlaxoSmithKline plc
GSK
|
$ 50.38 | -1.51 % | $ 204 B | NYSE |  Britain |
 |
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | USA |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 4.6 | -9.88 % | $ 39.2 M | Nasdaq Global Select Market | USA |
 |
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Taysha Gene Therapies
TSHA
|
$ 4.09 | -6.31 % | $ 1.31 B | Nasdaq Global Select Market | USA |
 |
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | USA |
 |
Annovis Bio
ANVS
|
$ 0.64 | -46.19 % | $ 13.2 M | NYSE American | USA |
 |
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | USA |
 |
United Therapeutics Corporation
UTHR
|
$ 565.49 | -7.07 % | $ 25.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | USA |
 |
Veracyte
VCYT
|
$ 23.51 | -55.24 % | $ 1.85 B | Nasdaq Global Market,SPB | USA |
 |
Viking Therapeutics
VKTX
|
$ 25.78 | -7.83 % | $ 2.9 B | Nasdaq Capital Market | USA |
 |
Idera Pharmaceuticals
IDRA
|
- | -23.04 % | $ 26.6 M | Nasdaq Global Select Market | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.08 | -10.85 % | $ 32.8 M | Nasdaq Global Market | USA |
 |
Viridian Therapeutics
VRDN
|
$ 28.53 | -1.81 % | $ 2.91 B | Nasdaq Capital Market | USA |
 |
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | USA |
 |
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | USA |
 |
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | USA |
 |
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | USA |
 |
Immunome
IMNM
|
$ 17.86 | -8.5 % | $ 1.56 B | Nasdaq Global Select Market | USA |
 |
Immuron Limited
IMRN
|
$ 0.85 | -0.01 % | $ 196 M | Nasdaq Global Select Market |  Australia |
 |
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market |  Canada |
 |
Immunic
IMUX
|
$ 7.44 | -6.3 % | $ 1.16 B | Nasdaq Global Select Market | USA |
 |
Incyte Corporation
INCY
|
$ 118.15 | -3.83 % | $ 23.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Cocrystal Pharma
COCP
|
$ 1.0 | -0.99 % | $ 11.3 M | Nasdaq Capital Market | USA |
 |
Atea Pharmaceuticals
AVIR
|
$ 4.2 | -5.83 % | $ 342 M | Nasdaq Global Select Market | USA |
 |
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | USA |
 |
INmune Bio
INMB
|
$ 1.18 | -11.14 % | $ 29.2 M | Nasdaq Capital Market | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | Canada |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
X4 Pharmaceuticals
XFOR
|
$ 3.06 | -5.56 % | $ 129 M | Nasdaq Capital Market | USA |
 |
Xencor
XNCR
|
$ 34.0 | -2.94 % | $ 2.52 B | Nasdaq Global Select Market,SPB | USA |
 |
Jounce Therapeutics
JNCE
|
- | - | $ 98.4 M | Nasdaq Global Select Market | USA |
 |
Verona Pharma plc
VRNA
|
- | - | $ 69.7 B | Nasdaq Global Select Market | Britain |
 |
Zai Lab Limited
ZLAB
|
$ 22.61 | -0.83 % | $ 24.8 B | Nasdaq Global Select Market |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 1.72 | -2.56 % | $ 124 M | Nasdaq Global Market | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
- | -0.89 % | $ 114 M | Nasdaq Global Select Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.